These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26559049)

  • 21. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis.
    Caldeira D; Costa J; Barra M; Pinto FJ; Ferreira JJ
    Thromb Res; 2015 Jan; 135(1):58-61. PubMed ID: 25456003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke.
    Mac Grory B; Holmes DN; Matsouaka RA; Shah S; Chang CWJ; Rison R; Jindal J; Holmstedt C; Logan WR; Corral C; Mackey JS; Gee JR; Bonovich D; Walker J; Gropen T; Benesch C; Dissin J; Pandey H; Wang D; Unverdorben M; Hernandez AF; Reeves M; Smith EE; Schwamm LH; Bhatt DL; Saver JL; Fonarow GC; Peterson ED; Xian Y
    JAMA; 2023 Jun; 329(23):2038-2049. PubMed ID: 37338878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
    García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
    PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?
    Steib A; Barre J; Mertes M; Morel MH; Nathan N; Ozier Y; Treger M; Samama CM
    J Thromb Haemost; 2010 Mar; 8(3):499-503. PubMed ID: 19912513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
    Stergiopoulos K; Brown DL
    JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of treatment with vitamin K antagonists: recombinant thromboplastins are more sensitive to factor VII than tissue-extract thromboplastins.
    Biedermann JS; van den Besselaar AM; de Maat MP; Leebeek FW; Kruip MJ
    J Thromb Haemost; 2017 Mar; 15(3):500-506. PubMed ID: 28055147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study.
    Biedermann JS; van Rein N; van den Besselaar AM; Buhre PN; de Maat MP; van der Meer FJ; Leebeek FW; Kruip MJ
    J Thromb Haemost; 2016 Apr; 14(4):695-703. PubMed ID: 26806724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential drug-drug interaction between proton pump inhibitors and warfarin.
    Henriksen DP; Stage TB; Hansen MR; Rasmussen L; Damkier P; Pottegård A
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1337-40. PubMed ID: 26395871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists.
    Daher J; Da Costa A; Hilaire C; Ferreira T; Pierrard R; Guichard JB; Romeyer C; Isaaz K
    Clin Drug Investig; 2020 Apr; 40(4):343-353. PubMed ID: 32144651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self- versus conventional management of oral anticoagulant therapy: effects on INR variability and coumarin dose in a randomized controlled trial.
    Christensen TD; Maegaard M; Sørensen HT; Hjortdal VE; Hasenkam JM
    Am J Cardiovasc Drugs; 2007; 7(3):191-7. PubMed ID: 17610346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Flucloxacillin on Warfarin Anticoagulation: A Swedish Register-Based Nationwide Cohort Study.
    Mannheimer B; Stage TB; Pottegård A; Lindh JD
    Thromb Haemost; 2019 Oct; 119(10):1617-1623. PubMed ID: 31352678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
    Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
    Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.
    Iorio A; Basileo M; Marcucci M; Guercini F; Camilloni B; Paccamiccio E; Vecchioli M; Iorio AM
    Arch Intern Med; 2010 Apr; 170(7):609-16. PubMed ID: 20386004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.